Literature DB >> 8755719

Activation of phospholipase A2 by amyloid beta-peptides in vitro.

J Y Lehtonen1, J M Holopainen, P K Kinnunen.   

Abstract

Amyloid beta-peptides (A beta) are centrally involved in the pathogenesis of Alzheimer's disease. Using secretory phospholipase A2 (PLA2) from porcine pancreas as a model and in the presence of a limiting Ca2+ concentration of approximately 50 nM, the synthetic peptide A beta 1-42 activates the hydrolysis of the pyrene-labeled acidic phospholipid analog 1-palmitoyl-2-[(pyren-1-yl)]hexanoyl-sn-glycero-3-phosphoglycerol (PPHPG) maximally 2.3-fold, whereas an inhibition of PLA2 action by 50% on the corresponding phosphatidylcholine derivative (PPHPC) was observed. The above effects were evident at 0.24 nM A beta 1-42 corresponding to A beta 1-42:phospholipid and A beta 1-42:PLA2 molar ratios of 1:10 650 and 1:7.6, respectively. The presence of 10 mol % 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) in PPHPC reversed the inhibitory effect of A beta 1-42 peptide and for these vesicles the hydrolytic activity of PLA2 toward the fluorescent phosphatidylcholine was enhanced approximately 1.8-fold by A beta 1-42. In contrast, inclusion of 10 mol % POPG into PPHPG did not influence either the hydrolytic rate toward the latter lipid or the activating effect of A beta 1-42. Ca2+ concentrations exceeding 15 microM abolished the enhancing effect of A beta 1-42 on the hydrolysis of PPHPG whereas a slight activation of PPHPC hydrolysis now became evident. With limiting [Ca2+] preaggregated A beta 1-42 enhanced the hydrolysis of both PPHPG as well as PPHPC but the peptide concentrations required were higher by 3-4 orders of magnitude. The synthetic peptide A beta 25-35 corresponding to the hydrophobic membrane-spanning segment of the beta amyloid precursor protein activated PLA2 when using PPHPG as a substrate; however, compared to A beta 1-42 the extent of activation was less (approximately 2-fold) and required higher (1 nM) peptide. A beta 25-35 did not affect the hydrolysis of the phosphatidylcholine derivative. The hydrophilic peptide A beta 1-28 had no effect on PLA2-catalyzed hydrolysis of either PPHPG or PPHPC under the conditions used in the present study. Interestingly, the above activating effects of A beta 1-42 and A beta 25-35 on PLA2-catalyzed hydrolysis of the acidic phospholipid substrate parallel their toxicity on cultured neurons whereas A beta 1-28 had no influence either on cultured cells or on PLA2 activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755719     DOI: 10.1021/bi960148o

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

Review 1.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Sex-dependent actions of amyloid beta peptides on hippocampal choline carriers of postnatal rats.

Authors:  Z Kristofiková; J Rícný; I Kozmiková; D Rípová; P Zach; J Klaschka
Journal:  Neurochem Res       Date:  2006-03       Impact factor: 3.996

3.  Amyloid beta peptide 1-40 and the function of rat hippocampal hemicholinium-3 sensitive choline carriers: effects of a proteolytic degradation in vitro.

Authors:  Z Kristofiková; H Tejkalová; J Klaschka
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

4.  Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex.

Authors:  Miki Igarashi; Kaizong Ma; Fei Gao; Hyung-Wook Kim; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

7.  Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET.

Authors:  Giuseppe Esposito; Giampiero Giovacchini; Jeih-San Liow; Abesh K Bhattacharjee; Dede Greenstein; Mark Schapiro; Mark Hallett; Peter Herscovitch; William C Eckelman; Richard E Carson; Stanley I Rapoport
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

8.  Amyloid-type fiber formation in control of enzyme action: interfacial activation of phospholipase A2.

Authors:  Christian Code; Yegor Domanov; Arimatti Jutila; Paavo K J Kinnunen
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

9.  Platelet phospholipase A2 activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke.

Authors:  E Krzystanek; M Krzystanek; G Opala; H I Trzeciak; J Siuda; A Małecki
Journal:  J Neural Transm (Vienna)       Date:  2007-04-20       Impact factor: 3.575

10.  Alzheimer disease and platelets: how's that relevant.

Authors:  Silvia Catricala; Mauro Torti; Giovanni Ricevuti
Journal:  Immun Ageing       Date:  2012-09-17       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.